Arcturus Therapeutics Holdings Inc
ARCT6.590USD
+0.060+0.92%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
179.48MMarket Cap
LossP/E TTM
More Details of Arcturus Therapeutics Holdings Inc Company
Arcturus Therapeutics Holdings Inc. is a commercial mRNA medicines and vaccines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. The Company with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. It has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The Company's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.
Arcturus Therapeutics Holdings Inc Info
Ticker SymbolARCT
Company nameArcturus Therapeutics Holdings Inc
IPO dateMay 22, 2013
CEOPayne (Joseph E)
Number of employees174
Security typeOrdinary Share
Fiscal year-endMay 22
Address10285 Science Center Drive
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92121-1132
Phone18589002660
Websitehttps://arcturusrx.com/
Ticker SymbolARCT
IPO dateMay 22, 2013
CEOPayne (Joseph E)
Company Executives of Arcturus Therapeutics Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Joseph E. Payne
Mr. Joseph E. Payne
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.48M
--
Dr. Padmanabh Chivukula
Dr. Padmanabh Chivukula
Chief Operating Officer, Chief Scientific Officer
Chief Operating Officer, Chief Scientific Officer
435.33K
--
Mr. Lance Kurata
Mr. Lance Kurata
Chief Legal Officer
Chief Legal Officer
--
--
Dr. Adm. Jing L. Marantz, M.D., Ph.D.
Dr. Adm. Jing L. Marantz, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Edward W. Holmes, M.D.
Dr. Edward W. Holmes, M.D.
Independent Director
Independent Director
--
--
Mr. James F. Barlow
Mr. James F. Barlow
Independent Director
Independent Director
--
--
Dr. John H. Markels, Ph.D.
Dr. John H. Markels, Ph.D.
Independent Director
Independent Director
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Andrew H. (Andy) Sassine
Mr. Andrew H. (Andy) Sassine
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Joseph E. Payne
Mr. Joseph E. Payne
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.48M
--
Dr. Padmanabh Chivukula
Dr. Padmanabh Chivukula
Chief Operating Officer, Chief Scientific Officer
Chief Operating Officer, Chief Scientific Officer
435.33K
--
Mr. Lance Kurata
Mr. Lance Kurata
Chief Legal Officer
Chief Legal Officer
--
--
Dr. Adm. Jing L. Marantz, M.D., Ph.D.
Dr. Adm. Jing L. Marantz, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Edward W. Holmes, M.D.
Dr. Edward W. Holmes, M.D.
Independent Director
Independent Director
--
--
Mr. James F. Barlow
Mr. James F. Barlow
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Federated Hermes Global Investment Management Corp.
12.64%
BlackRock Institutional Trust Company, N.A.
5.67%
Amova Asset Management Co., Ltd.
5.24%
The Vanguard Group, Inc.
5.08%
ARK Investment Management LLC
5.04%
Other
66.34%
Shareholders
Shareholders
Proportion
Federated Hermes Global Investment Management Corp.
12.64%
BlackRock Institutional Trust Company, N.A.
5.67%
Amova Asset Management Co., Ltd.
5.24%
The Vanguard Group, Inc.
5.08%
ARK Investment Management LLC
5.04%
Other
66.34%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
31.31%
Investment Advisor
23.03%
Hedge Fund
5.93%
Individual Investor
5.76%
Research Firm
4.49%
Insurance Company
1.15%
Bank and Trust
0.11%
Pension Fund
0.07%
Other
28.14%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
379
24.41M
101.05%
+65.19K
2025Q3
390
24.39M
105.94%
-108.18K
2025Q2
391
24.51M
106.05%
-785.15K
2025Q1
389
25.39M
104.98%
-3.08M
2024Q4
389
25.36M
100.87%
+927.22K
2024Q3
392
24.59M
103.35%
-885.79K
2024Q2
397
25.42M
103.89%
-1.17M
2024Q1
382
26.57M
98.31%
+105.67K
2023Q4
370
24.70M
96.75%
+284.54K
2023Q3
366
24.38M
91.83%
+1.44M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Federated Hermes Global Investment Management Corp.
4.69M
17.29%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.14M
7.9%
+24.09K
+1.14%
Jun 30, 2025
Amova Asset Management Co., Ltd.
1.83M
6.75%
-93.62K
-4.86%
Jun 30, 2025
The Vanguard Group, Inc.
1.81M
6.67%
+66.51K
+3.81%
Jun 30, 2025
ARK Investment Management LLC
1.72M
6.32%
-293.44K
-14.61%
Jun 30, 2025
Payne (Joseph E)
1.48M
5.45%
--
--
Apr 08, 2025
State Street Investment Management (US)
1.02M
3.76%
-260.68K
-20.36%
Jun 30, 2025
Balyasny Asset Management LP
864.10K
3.18%
-74.09K
-7.90%
Jun 30, 2025
Morgan Stanley & Co. LLC
595.02K
2.19%
+64.55K
+12.17%
Jun 30, 2025
Schonfeld Strategic Advisors LLC
784.41K
2.89%
-41.36K
-5.01%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ARK Genomic Revolution ETF
2.2%
WisdomTree BioRevolution Fund
1.23%
Virtus LifeSci Biotech Clinical Trials ETF
0.53%
iShares Genomics Immunology and Healthcare ETF
0.53%
AXS Green Alpha ETF
0.37%
Global X Genomics & Biotechnology ETF
0.27%
ALPS Medical Breakthroughs ETF
0.11%
State Street SPDR S&P Biotech ETF
0.09%
iShares Micro-Cap ETF
0.05%
Direxion Daily S&P Biotech Bull 3X Shares
0.05%
View more
ARK Genomic Revolution ETF
Proportion2.2%
WisdomTree BioRevolution Fund
Proportion1.23%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.53%
iShares Genomics Immunology and Healthcare ETF
Proportion0.53%
AXS Green Alpha ETF
Proportion0.37%
Global X Genomics & Biotechnology ETF
Proportion0.27%
ALPS Medical Breakthroughs ETF
Proportion0.11%
State Street SPDR S&P Biotech ETF
Proportion0.09%
iShares Micro-Cap ETF
Proportion0.05%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.05%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Arcturus Therapeutics Holdings Inc?
The top five shareholders of Arcturus Therapeutics Holdings Inc are:
Federated Hermes Global Investment Management Corp. holds 4.69M shares, accounting for 17.29% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.14M shares, accounting for 7.90% of the total shares.
Amova Asset Management Co., Ltd. holds 1.83M shares, accounting for 6.75% of the total shares.
The Vanguard Group, Inc. holds 1.81M shares, accounting for 6.67% of the total shares.
ARK Investment Management LLC holds 1.72M shares, accounting for 6.32% of the total shares.
Federated Hermes Global Investment Management Corp. holds 4.69M shares, accounting for 17.29% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.14M shares, accounting for 7.90% of the total shares.
Amova Asset Management Co., Ltd. holds 1.83M shares, accounting for 6.75% of the total shares.
The Vanguard Group, Inc. holds 1.81M shares, accounting for 6.67% of the total shares.
ARK Investment Management LLC holds 1.72M shares, accounting for 6.32% of the total shares.
What are the top three shareholder types of Arcturus Therapeutics Holdings Inc?
The top three shareholder types of Arcturus Therapeutics Holdings Inc are:
Federated Hermes Global Investment Management Corp.
BlackRock Institutional Trust Company, N.A.
Amova Asset Management Co., Ltd.
Federated Hermes Global Investment Management Corp.
BlackRock Institutional Trust Company, N.A.
Amova Asset Management Co., Ltd.
How many institutions hold shares of Arcturus Therapeutics Holdings Inc (ARCT)?
As of 2025Q4, 379 institutions hold shares of Arcturus Therapeutics Holdings Inc, with a combined market value of approximately 24.41M, accounting for 101.05% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -4.89%.
What is the biggest source of revenue for Arcturus Therapeutics Holdings Inc?
In --, the -- business generated the highest revenue for Arcturus Therapeutics Holdings Inc, amounting to -- and accounting for --% of total revenue.
